Millendo develops novel, disease-modifying treatments for specialty and orphan endocrine diseases caused by hormone dysregulation.

Learn More

February 2, 2016
Millendo Therapeutics to Present at Four Upcoming Conferences
Read More >>

January 5, 2016
Millendo Licenses Phase 2 Polycystic Ovary Syndrome (PCOS) Drug Candidate from AstraZeneca and Secures Series B Financing of $62 Million to Advance Pipeline of Endocrine Disorder Therapies
Read More >>